Piceatannol is a resveratrol-related plant compound from passion-fruit seeds, sold as a niche supplement. Human evidence is thin: short studies hint at better insulin response in overweight men and modest skin benefits, while broader claims rest on cell and animal work. It clears the body fast, seems well tolerated short-term, but stays early-stage. (Full Review)

Protocol

Standard Dose

20 mg/day

Only human-tested oral dose, as passion-fruit-seed extract, taken for 8 weeks

Dosing Pattern

Once daily

Once-daily is the only evidence-based pattern despite rapid clearance

Best Time of Day

With a meal

Reasonable to align with post-meal metabolic handling; no timing study exists

Time to effect

Metabolic Markers

8 weeks

Insulin and blood-pressure changes were measured at this point in the trial

SIRT1 Expression

2 weeks

Raised SIRT1 gene activity in blood after two weeks of dosing

Skin Outcomes

Over weeks

Skin hydration and wrinkle outcomes accrued gradually over weeks

Benefits

Low: Improved insulin sensitivity in overweight men; increased SIRT1 expression; skin hydration and wrinkle reduction

Speculative: Anti-inflammatory and immune-modulating effects; cardiovascular protection; anticancer and chemopreventive activity; neuroprotection; anti-obesity / fat metabolism

Contraindications

Pregnancy or breastfeeding

Bleeding disorders or surgery within ~2 weeks

Anticoagulant use without supervision

Hormone-sensitive cancers

Key Interactions

Anticoagulant and antiplatelet drugs (warfarin, apixaban, rivaroxaban, aspirin, clopidogrel)

Over-the-counter NSAIDs (ibuprofen, naproxen, high-dose aspirin)

Blood-thinning supplements (fish oil, high-dose vitamin E, ginkgo, garlic, curcumin)

Additive antioxidant/sirtuin supplements (resveratrol, pterostilbene, quercetin)

COMT-dependent drugs and substrates (entacapone, catecholamine-based medications)

Risk & Side Effects

Low: Generally mild tolerability with limited safety data

Speculative: Bleeding / antiplatelet risk; estrogenic / hormonal activity; drug-metabolism interactions; pregnancy and lactation uncertainty

Monitoring

Marker	Target	Why
Fasting insulin	2–5 µIU/mL	Most direct marker of the trial's primary benefit
Fasting glucose	75–90 mg/dL	Tracks glucose control alongside insulin
HbA1c	< 5.4%	Longer-term (3-month) glucose average
Blood pressure	< 120/80 mmHg	Trial showed reductions in overweight men
Resting heart rate	50–70 bpm	Reduced in the trial subgroup
hs-CRP	< 1.0 mg/L	Gauges any anti-inflammatory effect
Lipid panel (LDL, HDL, triglycerides)	LDL < 100 mg/dL; triglycerides < 100 mg/dL	Cardiovascular mechanism is proposed

Cadence: Baseline, then around 8–12 weeks, and thereafter every 6–12 months if use continues

Qualitative Assessment

Energy levels and exercise tolerance
Skin hydration and appearance
Body composition and waist measurement
General well-being and any signs of easy bruising or bleeding

Piceatannol for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment